Joshua J. Meeks, MD, PhD, explains how enfortumab vedotin plus pembrolizumab is reshaping organ preservation in MIBC.
|Videos|August 23, 2017
Dr. Gupta on PD-L1 as a Biomarker in Kidney Cancer
Author(s)Shilpa Gupta, MD, Cleveland Clinic
Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses PD-L1 as a biomarker in kidney cancer.
Advertisement
Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses PD-L1 as a biomarker in kidney cancer.
The biomarker question is something that needs to be tackled, says Gupta. Additionally, in kidney cancer, it is not known whether PD-L1 is a predictive biomarker.
Advertisement
Related to this article
Experts break down key kidney cancer data and trends from the 2026 ESMO Congress.
Praful Ravi, MB, BChir, MRCP, discusses the LASER futility readout, PSMA heterogeneity in clear cell RCC, and next steps for radiopharmaceuticals.
Daniel Heng, MD, MPH, FRCPC, discusses data from LITESPARK-011, second-line RCC sequencing, and managing belzutifan-associated anemia and hypoxia.
Advertisement
Advertisement
Trending on OncLive
1
RP1 Plus Nivolumab Preserves Quality-Adjusted Survival in Advanced Melanoma After Anti–PD-1 Therapy
2
Afami-Cel Outcomes Are Tied to MAGE-A4 Expression, Tumor Burden in Synovial Sarcoma
3
STX-001 Produces Durable Systemic Responses in PD-1–Resistant Melanoma
4
VET3-TGI Generates Responses in Checkpoint Inhibitor–Refractory Cutaneous Cancers
5